Jing Lou, CEO of 3SBio. ‘This purchase allows 3SBio to get access to the very best external science and small molecule medication discovery platform in China.’ ‘Apoptosis targeted small molecule has the potential to play an integral role in the next generation of impressive targeted cancer medicines,’ stated Dr. Dajun Yang, CEO of Ascentage Pharma. ‘We think that this ‘win-earn’ collaboration will generate innovative medications that benefits patients world-wide.’ SOURCE 3SBio Inc..Allen & Overy acted as legal advisor to Misys. Highlights of Secondary Share and Offering Buyback of Allscripts Shares owned by Misys In connection with the merger, Allscripts will facilitate a reduction of Misys’s collateral stake in Allscripts from approximately 55 percent to approximately 10 percent through an underwritten secondary collateral offering and talk about buyback. This reduction in equity stake will enable Misys to keep up compliance with listing requirements of the uk listing authorities. Misys will sell off to the general public in the secondary supplying a minimum of around 36 million of its Allscripts shares. Additionally, Allscripts shall buy back again from Misys, concurrent with the closing of the secondary offering, approximately 24.4 million of its Allscripts shares at a cost of $18.82 per talk about, or $460 million altogether, and also a payment of reduced of $117.4 million regarding the the sale by Misys of its controlling curiosity, for a total of $577.4 million.